Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03953560
Other study ID # 0034667956480
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 16, 2019
Est. completion date February 15, 2022

Study information

Verified date March 2022
Source Hospitales Universitarios Virgen del Rocío
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Routine screening for Chronic thromboembolic pulmonary hypertension (CTEPH) i after PE is not supported by current evidence and guidelines. This study aims to evaluate if a screening program for patients with acute PE based on telephone monitoring of symptoms and further examination if only symptomatic patients could help an early detection of CTEPH.


Description:

Chronic thromboembolic pulmonary hypertension (CTEPH) is a long-term complication following an acute or silent pulmonary embolism (PE). A history of acute PE was reported in 75% of CTEPH patients. Nevertheless, incidence of CTEPH after a confirmed acute PE vary widely depending of the studies, with estimated incidence from 0.5 to 4%. Performing a follow-up examination of patients diagnosed with acute PE regardless of persisting symptoms and using all available technical procedures is not cost-effective. As a consequence, routine screening for CTEPH after PE is not supported by current evidence and guidelines. CTEPH is a very disabling and mortal disease, although it is a potential curable disease. However, delayed diagnosis and misdiagnosis is common. Patients are frequently diagnosed with CTEPH at advanced stages of the disease leading to worse clinical outcomes. Early diagnosis of CTEPH is essential, as delay in diagnosis may be associated with a worse prognosis, higher perioperative mortality and inoperable diseases stages. Overall, evidence from various sources suggests that early detection and treatment of CTEPH is advantageous in achieving favorable clinical outcomes. Therefore, there is an important unmet need for early diagnosing this disease. Focusing diagnostic procedures only on symptomatic patients may be a practical approach for detecting relevant CTEPH. This study aims to evaluate if a screening program for patients with acute PE based on telephone monitoring of symptoms and further examination if only symptomatic patients could help an early detection of CTEPH. Objectives - Primary outcome: To estimate the impact of an easy and simple strategy to identify CTEPH. - Secondary outcomes: - To identify patients with CTED after PE - To obtain external validation from scores to identify patients at risk to develop CTEPH - To develop new score to identify high risk population to develop CTEPH Hypothesis Conceptual hypothesis: The use of a strategy to detect CTEPH will increase number of patients diagnosed of pulmonary hypertension. Operational hypothesis: The use of a strategy to detect CTEPH will increase in a 200% the number of patients diagnosed with CTEPH. Design Cohorts study in consecutive patients with objectively confirmed PE. Specialists implied Internal medicine, Pulmonologist, Hematologist from 20 hospitals. Inclusion criteria: 1) Age > 18 year 2) Objectively confirmed diagnosis of acute PE by multidetector CT, V/Q lung scan, or selective pulmonary angiography, according to established diagnostic criteria, with or without symptomatic DVT, 3) Ability of subject to understand the character and consequences of the study, 4) informed consent of the subject. Exclusion criteria: refused informed consent, inability to cooperation. Intervention Investigator from each center will recover consecutive PE patients and collect baseline, demographic and co-morbidities. In all patients enrolled in the study a short questionnaire regarding dyspnea symptoms will be performed. All patients that refer dyspnea grade ≥ II according NYHA-WHO modified scale will be cited as outpatient to be evaluated A written informed consent will be required all patients evaluated in consultant. Imaging studies and right heart catheterization is the procedure agreeing with the standard care according to current ESC/ERS Guidelines. In all patients, the following tests will be performed: 1. Pulsioximetry. 2. Electrocardiogram. 3. Blood sample with determination of NT-ProBNP. 4. Echocardiography. Only an echocardiography indicative of PH warrants further evaluation 5. V/Q scintigraphy. Possible CTEPH can be assumed when mismatched perfusion defects are detected by VQ scan. 6. Right heart catheterization & Pulmonary CT Scan are required for confirming the diagnosis The relationship of Doppler echocardiography-estimated PASP with right heart catheterization (RHC)-measured PASP was examined using Spearman's correlation coefficients. The Bland-Altman method was then used to assess the agreement between Doppler echocardiography-estimated and RHC measured PASP. Doppler echocardiography-estimated PASP within +/- 10mmHg of the value measured on RHC was considered accurate, consistent with the cutoffs used in other publications. Secondary outcome include number of patients with chronic thromboembolic disease (CTED), described as chronic thromboembolic pulmonary vascular obstruction with normal resting pulmonary artery pressures. Treatment: No treatment required Statistical Plans Sample size calculation We estimate CTEPH prevalence in reference group of 1%, and a prevalence of CTEPH in interventional group of 2.8%. With unilateral test, con confidence level of 95%, statistic power of 80% and losses expected of 25%, we calculated a final sample size of 947. The investigators calculate that 16-20 centers in Spain are needed to recruit patients Investigators will compare baseline characteristics of patients with and without CTEPH using chi-square tests for categorical variables and non-parametric rank tests for continuous variables. Cumulative incidence of CTEPH will be estimated using the Kaplan-Meier technique. To do external validation of previous score to predict CTEPH discriminative power by calculating the area under the receiver-operating characteristic (ROC) curve will be done, performing a non-parametric test of the equality of the areas under the ROC curves. Goodness-of-fit of the score points for each score in a logistic regression model using Pearson's chi-square test. Student's t test and X2 test (or Fisher's exact test where appropriate) will be used to compare continuous or categorical variables, and multivariable analysis through a logistic regression model using the Wald method (step back) to identify independent predictors for the occurrence of CTEPH. Covariates entering in the model will be selected by a significance level of p <0.20 on univariable analysis, or by a well-known association reported in the literature. Then, the investigators will build a prognostic score assigning points to each independent variable according to regression coefficients β, rounding to the nearest integer. The investigators will assign a risk score to each patient by adding up points for each independent variable. Performance will be quantified in terms of calibration using the Hosmer-Lemeshow test. Model discrimination will be assessed using the C-statistic. Internal validity of the score will be confirmed using bootstrap analysis. For the statistical analysis the investigators will use the IBM SPSS Statistics program (version 19; SPSS Inc., Chicago, IL), and a two-sided p<0.05 was considered to be statistically significant.


Recruitment information / eligibility

Status Completed
Enrollment 646
Est. completion date February 15, 2022
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age > 18 year 2. Objectively confirmed diagnosis of acute PE by multidetector CT, V/Q lung scan, or selective pulmonary angiography, according to established diagnostic criteria, with or without symptomatic DVT, 3. Ability of subject to understand the character and consequences of the study, 4. informed consent of the subject. Exclusion Criteria: - refused informed consent, inability to cooperation.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
dyspnea grade = II according NYHA-WHO
Intervention Investigator from each center will recover consecutives PE patients and collect baseline, demographic and comorbidities. In all patients enrolled in the study a short questionnaire regarding dyspnea symptoms will be performed. All patients that refer dyspnea grade = II according NYHA-WHO (6) modified scale will be cited as outpatient to be evaluated Imaging studies and right heart catheterization is the procedure agreeing with the standard care according to current ESC/ERS Guidelines. In all patients, the following tests will be performed: Pulsioximetry. Electrocardiogram. Blood sample with determination of NT-ProBNP. Echocardiography. Only an echocardiography indicative of PH warrants further evaluation V/Q scintigraphy. Possible CTEPH can be assumed when mismatched perfusion defects are detected by VQ scan. Right heart catheterization & Pulmonary CT Scan are required for confirming the diagnosis

Locations

Country Name City State
Spain Hospital General Universitario de Albacete Albacete
Spain Hospital Universitario de Bellvitge Barcelona
Spain Parc Sanitari Sant Joan de Deu Barcelona
Spain Consorcio Hospitalario Provincial de Castellón Castellón De La Plana Castellon
Spain Hospital Universitario Reina Sofía Córdoba
Spain Hospital Virgen de la Luz Cuenca
Spain Hospital General Universitario de Elche Elche
Spain Hospital de Galdakao Galdakao Vizcaya
Spain Hospital Universitari de Girona Dr. Josep Trueta Gerona
Spain Hospital Universitari Arnau de Vilanova Lerida
Spain Hospital Clínico San Carlos Madrid
Spain Hospital Universitario 12 de Octubre Madrid
Spain Hospital Universitario Puerto Real Puerto Real Cadiz
Spain Hospital Virgen del Rocio Sevilla
Spain Hospital Universitario Joan XXIII de Tarragona Tarragona
Spain Hospital Clínico Universitario Lozano Blesa Zaragoza

Sponsors (3)

Lead Sponsor Collaborator
Luis Jara-Palomares, MD Merck Sharp & Dohme Corp., Sociedad Española de Neumología y Cirugía Torácica

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of new diagnosis of CTEPH New diagnosis of CTEPH Up 3 years after PE
Secondary External validation from score to identify patients at risk to develop CTEPH external validation from score (Klok FA et al. Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. J Thromb Haemost. 2016) Up 3 years after PE
Secondary Derivation of a score to identify high risk population to develop CTEPH With variables assocciated to CTEPH investigators will obtain derivation and validation of a score to identify high risk population to develop CTEPH Up 3 years after PE
Secondary Number of patients with Chronic Thromboembolic Disease (CTED) after PE Describe the number and clinical characteristics of patients with CTED after PE Up 3 years after PE
See also
  Status Clinical Trial Phase
Recruiting NCT05050617 - Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
Terminated NCT04558125 - Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism Phase 4
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Completed NCT03915925 - Short-term Clinical Deterioration After Acute Pulmonary Embolism
Completed NCT02502396 - Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
Recruiting NCT05171075 - A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE Phase 3
Completed NCT04454554 - Prevalence of Pulmonary Embolism in Patients With Dyspnea on Exertion (PEDIS)
Completed NCT03173066 - Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography Phase 1
Terminated NCT03002467 - Impact Analysis of Prognostic Stratification for Pulmonary Embolism N/A
Completed NCT02334007 - Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery Phase 1/Phase 2
Completed NCT02611115 - Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography. N/A
Completed NCT01975090 - The SENTRY Clinical Study N/A
Not yet recruiting NCT01357941 - Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE) N/A
Completed NCT01326507 - Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism N/A
Completed NCT00773448 - Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism N/A
Completed NCT02476526 - Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease Phase 4
Completed NCT00780767 - Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism Phase 2
Completed NCT00720915 - D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months N/A
Completed NCT00771303 - Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
Completed NCT00816920 - Natural History of Isolated Deep Vein Thrombosis of the Calf